Findings

What do systematic reviews say?

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Exercise therapy vs control

Physical functioning End of treatment and long term · men and women aged over 18 years with chronic fatigue syndrome

1 finding from 1 review

Exercise therapy for chronic fatigue syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 725 participants
Low

Exercise therapy vs control

Physical functioning component of health‐related quality of life, measured using various scales · men and women aged over 18 years with chronic fatigue syndrome

1 finding from 1 review

Exercise therapy for chronic fatigue syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 621 participants
Very low

Exercise therapy vs control

QoL · men and women aged over 18 years with chronic fatigue syndrome

The review found no eligible studies for this question.

2 findings from 1 review

Exercise therapy for chronic fatigue syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Exercise therapy for chronic fatigue syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 710 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.35, 1.99]
2 studies · 656 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.21, 3.28]
2 studies · 656 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Pain ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy may leads to higher pain ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 2.44 [1.69, 3.55]
1 study · 596 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Stem cell therapy vs control

All‐cause mortality · DCM (non‐ischaemic)

It is very uncertain whether stem cell therapy changes all‐cause mortality compared with control (very low certainty).

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
RR 0.84 [0.54, 1.31]
7 studies · 361 participants
Very low

Stem cell therapy vs control

Procedural complications · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 361 participants
Very low

Stem cell therapy vs control

Health‐related quality of life · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 272 participants
Very low

Stem cell therapy vs control

Functional capacityAssessed: 6MWT · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 230 participants
Very low

Stem cell therapy vs control

Performance status – change in functional class (NYHA) · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 398 participants
Low

Stem cell therapy vs control

MACE · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Stem cell therapy vs control

Ventricular arrhythmias (within 30 days) · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 504 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Overall survival ‐ first‐line studies · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in overall survival ‐ first‐line studies compared with placebo or standard of care (moderate certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
HR 0.89 [0.76, 1.04]
3 studies · 1000 participants
Moderate

Anti‐EGFR therapy vs placebo or usual care

Overall survival ‐ recurrent disease studies · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in overall survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
HR 0.79 [0.51, 1.21]
4 studies · 489 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Lymphopenia · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in lymphopenia compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
OR 0.97 [0.19, 4.81]
4 studies · 1146 participants
Low